product description page

Mtor Inhibition for Cancer Therapy : Past, Present and Future (Hardcover)

Mtor Inhibition for Cancer Therapy : Past, Present and Future (Hardcover) - image 1 of 1

about this item

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs.

Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.

Number of Pages: 400.0
Genre: Medical
Sub-Genre: Oncology
Language: English
Book format: Hardcover
Pricing Code - MMBV: 6.0
Publisher - MMBV: Springer Verlag
Street Date: December 1, 2015
TCIN: 50920611
UPC: 9782817804910
Item Number (DPCI): 248-12-6393

guest reviews

Prices, promotions, styles and availability may vary by store & online. See our price match guarantee. See how a store is chosen for you.